Oct 14, 2024 | News, Press Release
Bruce L.A. Carter, PhD, and Paul Sekhri join Board of Directors, adding drug development and operating experience Recent board additions highlight Kayothera’s evolution into pipeline-focused organization with meaningful translational efforts Seattle, WA —... Sep 18, 2023 | News, Press Release
Unique safety profile positions KAYO-1609 as the first retinoid pathway inhibitor to enter Investigational New Drug (IND)-enabling studies Company expects to file IND application with the U.S. Food & Drug Administration (FDA) by the end of 2024 Seattle, WA —... Jul 19, 2023 | News, Press Release
New funding comprised of grants from the National Institutes of Health, The Andy Hill Cancer Research Endowment (CARE) Fund, and additional Equity Funding Additional funding will support advancement of KayoThera’s development programs in diabetes and oncology... Feb 2, 2023 | News, Press Release
Seattle, WA — February 02, 2023, A paper published today in the peer-reviewed journal Nature Communications, co-authored by researchers from Columbia University, Kayothera, Inc., and Princeton University, describes a new therapeutic strategy for treatment of type 2... Mar 16, 2022 | News, Press Release
Novel Approach to Treat Late-Stage and Metastatic Cancers SEATTLE, WA – March 16, 2022, KayoThera, Inc. (“KayoThera”), an early-stage therapeutics company developing novel cancer immunotherapies, today announces the closing of an $8 million Series A round of...